Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor

Journal of Immunology

Volumn 164, Issue 2, 2000, Pages 916-925

  Dobrzanski, Mark J ^a   Reome, Joyce B ^a   Dutton, Richard W ^a  

^a TRUDEAU INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 4; INTERLEUKIN 5; OVALBUMIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; LUNG METASTASIS; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUPPRESSOR CELL;

EID: 0034650432     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.2.916     Document Type: Article

References (47)

1. Dutton, R. W., L. M. Bradley, and S. L. Swain. 1998. T cell memory. Annu. Rev. Immunol. 16:201.
2. Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281.
3. Schwartz, R. H. 1994. Models of T cell anergy: is there a common molecular mechanism. J. Exp. Med. 184:1.
4. Sprent, J., D. F. Tough, and S. Sun. 1997. Factors controlling the turnover of T memory cells. Immunol. Rev. 156:79.
5. Swain, S. L., M. Croft, C. Dubey, L. Haynes, M. P. Rogers, X. Zhang, and L. M. Bradley. 1996. From naive to memory T cells. Immunol. Rev. 150:1243.
6. Marrack, P., T. Mitchell, J. Bender, D. Hildeman. R. Kedl, K. Teague, and J. Kappler. 1998. T cell survival. Immunol. Rev. 165:279.
7. Vella, A. T., S. Dow, T. A. Potter, J. Kappler, and P. Marrack. 1998. Cytokine induced survival of activated T cells in vitro and in vivo. Proc. Natl. Acad. Sci. USA 95:3810.
8. Zhang, X., S. Sun, I. Hwang, D. F. Tough, and J. Sprent. 1998. Potent and selective stimulation of memory phenotype CD8 T cells in vivo by IL-15. Immunity 8:591.
9. Boehm, U., T. Klamp, J. C. Groot, and J. C. Howard. 1997. Cellular responses to interferon-γ. Annu. Rev. Immunol. 15:749.
10. Kundig, T. M., M. F. Bachmann, S. Oehen, U. W. Hoffmann, J. J. L. Simard, C. P. Kalberer, H. Pircher, P. S. Ohashi, H. Hengartner, and R. M. Zinkernagel. 1996. On the role of antigen in maintaining cytotoxic T cell memory. Prof. Natl. Acad. Sci. USA 93:9716.
11. Farber, D. L. 1998. Differential TCR signaling and the generation of memory T cells. J. Immunol. 160:535.
12. + T cell subpopulations in established pulmonary metastases. J. Immunol. 162:6671.
13. Croft, M., L. L. Carter, S. L. Swain, and R. W. Dutton. 1994. Generation of polarized antigen specific CD8 effector populations: reciprocal actions of IL-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med. 180:1715.
14. Sad, S., R. Marcotte, and T. R. Mosmann. 1995. Cytokine induced differentiation of precursor mouse CD8 T cells into cytotoxic CD8 T cells secreting Th1 or Th2 cytokines. Immunity 2:271.
15. Cerwenka, A., L. L. Carter, J. B. Reome, S. L. Swain, and R. W. Dutton. 1998. In vivo persistence of CD8 polarized T cell subsets producing type 1 or type 2 cytokines. J. Immunol. 161:97.
16. Hogquist, K. A., S. C. Jameson, W. R. Health, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonistic peptides induce positive selection. Cell 76:17.
17. Karasuyama, H., and F. Melchers. 1988. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4, or 5, using high-copy cDNA expression vectors. Eur. J. Immunol. 18:97.
18. Opferman, J. T., B. T. Ober, and P. G. Ashton-Rickardt. 1999. Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science 283:1745.
19. Ahmed, R. and D. Gray. 1996. Immunological memory and protective immunity: understanding their relation. Science 272:54.
20. Bohm, W., S. Thoma, F. Leithauser, P. Moller, R. Schirmbeck, and J. Reimann. 1998. T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas. J. Immunol. 161:897.
21. Krasagakis, K., C. Garbe, C. C. Zouboulis, and C. E. Orfanos. 1995. Growth control of melanoma cells and melanocytes by cytokines. Cancer Res. 139:169.
22. Griffith, T. S., S. R. Wiley, M. Z. Kubin, L. M. Sedger, C. R. Maliszewski, and N. A. Fanfer. 1999. Monocyte-mediated tumorcidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189:1343.
23. Webb, D. S., and T. L. Gerrard. 1990. IFN-α and IFN-γ can affect both monocytes and tumor cells to modulate monocyte-mediated cytotoxicity. J. Immunol. 144:3643.
24. Tepper, R. I., and J. J. Mule. 1994. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum. Gene Ther. 5:153.
25. Sgadari, C., A. L. Angiolillo, and G. Tosato. 1996. Inhibition of angiogenesis by interleukin 12 is mediated by the interferon-inducible protein-10. Blood 87:3877.
26. Sgadari, C., J. M. Farber, A. L. Angiolillo, F. Liao, J. Teryua-Feldstein, P. R. Burd, L. Yao, G. Gupta, C. Kanegane, and G. Tosato. 1997. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo. Blood 89: 2635.
27. Barth, R. J., Jr., J. J. Mule, P. J. Spiess, and S. A. Rosenberg. 1991. Interferon γ and tumor necrosis factor have a role in tumor regressions mediated by murine CD8 tumor-infiltrating lymphocytes. J. Exp. Med. 173:647.
28. Ogasawara, M., and S. A. Rosenberg. 1993. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with γ-interferon genes. Cancer Res. 53: 3561.
29. Kaplan, D. H., V. Shankaran, A. S. Dighe, E. Stockert, M. Auguet, L. J. Old, and R. D. Schreiber. 1998. Demonstration of an interferon-γ-dependent tumor surveillance system in immunocompetent mice. Prof. Natl. Acad. Sci. USA 95:7556.
30. Tepper, R., P. Pattengale, P. Leder. 1989. Murine interleukin-4 displays potent antitumor activity in vivo. Cell 57:503.
31. Golumbek, P., A. Lazenby, H. Levitsky, L. Jaffee, H. Karasuyama, M. Baker, and D. M. Pardoll. 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254:713.
32. Masuda, Y., S. Mita, K. Sakamoto, T. Ishiko, and M. Ogawa. 1995. Suppression of in vivo tumor growth by the transfection of the IL-5 gene into colon tumor cells. Cancer Immunol. Immunother. 41:325.
33. Noffz, G., Z. Qin, M. Kopf, and T. Blackenstein. 1998. Neutrophils but not eosinophils are involved in growth suppression of IL-4 secreting tumors. J. Immunol. 160:345.
34. Rivoltini, L., V. Viggiano, S. Spinazze, A. Santoro, M. P. Colombo, K. Takatsu, and G. Parmiani. 1993. In vitro antitumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin-2: role of interleukin-5. Int. J. Cancer 54:8.
35. Tepper, R. I., R. L. Coffman, and P. Leder. 1992. An eosinophil-dependent mechanism for the antitumor effect of IL-4. Science 257:548.
36. Li Li, Y. Xia, A. Nguyen, Y. H. Lai, L. Feng, T. R. Mosmann, and D. Lo. 1999. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potentially induces eotaxin expression by airway epithelial cells. J. Immunol. 162:2477.
37. Fujiwara, H., and T. Hamaoka. 1995. Regulatory mechanisms of antitumor T cell responses in the tumor-bearing state. Immunol. Res. 14:271.
38. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95:1178.
39. Jager, E., M. Ringhoffer, J. Karbach, M. Arand, F. Oesch, and A. Knuth. 1996. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8 cytotoxic T cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer 66:470.
40. Lehmann, F., M. Marchand, P. Hainaut, P. Pouillart, X. Sastre, H. Ikeda, T. Boon, and P. G. Coulie. 1995. Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur. J. Immunol. 25:340.
41. North, R. J. 1985. Down-regulation of the antitumor immune response. Adv. Cancer Res. 45:1.
42. Mukherji, B., A. Guha, N. G. Chakraborty, M. Sivanandham, A. L. Nashed, J. R. Sporn, and M. T. Ergin. 1989. Clonal analysis and regulatory T cell responses against human melanoma. J. Exp. Med. 169:1961.
43. Ochoa, A. C., and D. L. Longo. 1995. Alterations of signal transduction in T cells from cancer patients. In: Important Advances in Oncology. V. T. Devita, S. Hellman, and S. A. Rosenberg, eds. Lippincott, Philadelphia, p. 43.
44. Rabinowich, H., T. E. Reichert, Y. Kashii, B. R. Gastman, M. C. Bell, and T. L. Whiteside. 1998. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carinoma cells: implications for altered expression of T cell receptor in tumor-associated lymphocytes. J. Clin. Invest. 101:2579.
45. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L. E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, et al. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implication for tumor immune escape. Science 274:1363,
46. Vitetta, E. S., T. F. Tucker, E. Racila, Y. Huang, R. Marches, N. Lane, R. H. Scheuermann, N. E. Street, T. Watanabe, and J. W. Uhr. 1997. Tumor dormancy and cell signalling. V. Regrowth of the BCL-1 tumor after dormancy is established. Blood 89:4425.
47. Farrar, J. D., K. H. Katz, J. Windsor, G. Thrush, R. M. Scheuermann, J. W. Uhr, and N. E. Street. 1999. Cancer dormancy. VII. A Regulatory role for CD8 T cells and IFN-γ in establishing and maintaining the tumor dormant state. J. Immunol. 162:2842.